EFB Dengue Literature Review

DN2 B Cell

12 min read

DN2 B Cell

Overview

DN2 B cells are a subset of IgD⁻CD27⁻ (double-negative) B cells defined by the phenotype CXCR5⁻, CD21⁻, CD11c⁺, CD19^hi. They were formally defined by Jenks et al. (2018) as the dominant expanded DN population in active SLE, distinct from DN1 cells (CXCR5⁺, CD21⁺, CD19 intermediate) which transcriptionally resemble switched memory B cells.

DN2 cells are pre-plasmablasts: they express a T-bet/ZEB2 transcriptional programme, have high IRF4 and BLIMP-1, lack BACH2 and FOXO1, and differentiate into autoantibody-secreting plasmablasts in response to TLR7 + IL-21 + IFN-γ without requiring BCR stimulation or extensive cell division. They share phenotypic markers and a near-identical transcriptome with activated naive (aNAV) B cells, forming the intermediate step in the extrafollicular differentiation pathway: rNAV → aNAV → DN2 → plasmablast.

Key Points from Literature

  • Full phenotype: IgD⁻, CD27⁻, CXCR5⁻, CD21⁻, CD11c⁺, CD19^hi, CD24⁻, CD38⁻, CD62L^lo, MTG⁺, FCRL4⁻, FCRL5⁺. Higher expression of CD32b, CD22, CD69, HLA-DR, CD86 relative to NAV and SWM. Surface IgG 50% lower than DN1 or SWM (see Jenks2018 - DN2 B Cells and EF Pathway in SLE, two SLE cohorts N=90 + HCD N=21).

  • IgG3 enrichment: DN2 cells have a higher frequency of IgG3⁺ cells than SWM or DN1 in both HCD and SLE. IgG3 is the human equivalent of murine IgG2a (the dominant subclass in T-bet⁺ ABC-driven autoimmunity) and is the dominant IgG subclass deposited in lupus kidneys (see Jenks2018 - DN2 B Cells and EF Pathway in SLE).

  • Frequency in SLE: DN2 cells are a minor fraction of CD19⁺ and DN B cells in HCD (mean + 2 SD = 4.01% of CD19⁺), but represent the majority of DN cells and may become the dominant non-plasmablast CD19⁺ population in active SLE. Absolute DN2 counts are greatly elevated in SLE patients with high DN2 frequency (see Jenks2018 - DN2 B Cells and EF Pathway in SLE).

  • Transcriptional identity (RNA-seq): Over 1,000 DEGs separate DN2 from NAV and SWM. DN2-high: TBX21, ZEB2, IRF4, ITGAX, FCRL5, FCGR2B, PRDM1, SLAMF7, SPI1. DN2-low: BACH2, FOXP1, FOXO1, BCOR, TRAF5, TNFAIP3, BCL2, ZEB1, ETS1, TCF7, CXCR5, CR2. DN2 and aNAV cells have highly similar transcriptomes. DN1 and SWM differ by only 22 DEGs (see Jenks2018 - DN2 B Cells and EF Pathway in SLE, RNA-seq of sorted populations).

  • Poised for PC differentiation: High IRF4/low IRF8 ratio; low ETS1; BLIMP-1 (PRDM1) protein elevated above all B cells except PC; PRDM1 locus open by ATAC-seq; enrichment for IRF4 target genes expressed in PC by GSEA. SLAMF7 (PC marker) upregulated in DN2 and aNAV but no other B cells (see Jenks2018 - DN2 B Cells and EF Pathway in SLE).

  • TLR7 hyper-responsiveness: R848 (TLR7 agonist) induces strong pERK and pMAPKp38 phosphorylation in DN2 and aNAV but not in SWM, DN1, or NAV. CD40L stimulation increases CD25 in NAV but not DN2. Mechanistic basis: low TRAF5 (the main negative regulator of TLR signalling in B cells) (see Jenks2018 - DN2 B Cells and EF Pathway in SLE, phospho-flow cytometry n=5–10).

  • In vitro differentiation from rNAV: rNAV + TLR7 + IFN-γ + IL-21 generates aNAV (day 3), DN2 (day 3–5), and PC (day 5–7). Equal efficiency from SLE and HCD rNAV cells. IL-4 substitution blocks generation. CD40L inhibits aNAV/DN2 but not DN1 generation. aNAV cells directly differentiate into DN2 cells in 3-day cultures (see Jenks2018 - DN2 B Cells and EF Pathway in SLE, in vitro n=5).

  • DN2 → PC without BCR stimulation or cell division: DN2 cells stimulated with TLR7 + IL-21 + IFN-γ (signal 3 only) generate PC robustly, in the presence or absence of BCR stimulation, without extensive cell expansion. IgG output per cell equivalent to SWM cultures. TLR7 is required — removing R848 causes >95% cell death by day 7 (see Jenks2018 - DN2 B Cells and EF Pathway in SLE).

  • Autoantibody production: DN2 cell cultures produce anti-Sm, anti-RNP, and anti-Ro autoantibodies at titers comparable to SWM (see Jenks2018 - DN2 B Cells and EF Pathway in SLE, LIPS assay).

  • Clonal connectivity with aNAV and PC: BCR sequencing demonstrates clonal sharing between aNAV, DN2, and PC populations — in vivo evidence of the aNAV → DN2 → PC developmental pathway. IgG mutation rate in DN2 is similar to PC but lower than SWM, arguing against derivation from memory cells (see Jenks2018 - DN2 B Cells and EF Pathway in SLE).

  • Clinical associations: DN2 expansion is most prominent in African-American patients, patients with active nephritis, high SLEDAI, anti-Sm/RNP/RNA autoantibodies. No age dependence (present in a 5-year-old; Jenks2018 reported patients as young as 6). DN2 cells can contribute up to 70% of all blood CD19⁺ B cells in active SLE. Modestly correlated with type I IFN activity. Specifically linked to anti-Sm and anti-RNP titers by LIPS assay (see Jenks2018 - DN2 B Cells and EF Pathway in SLE; see also Sanz2025 - Human Atypical B Cells Overview, review).

  • DN2/DN1 ratio as an informative index: SLE patients typically display an elevated DN2/DN1 ratio even when total DN frequency is not greatly increased, making this calculation an informative index of disturbed B cell homeostasis (see Sanz2025 - Human Atypical B Cells Overview, review).

  • DN2 in RA synovium: DN2 cells in the rheumatoid synovium represent the main precursor of ASC (Wing et al. 2023, cited in Sanz2025 - Human Atypical B Cells Overview, review).

  • Cross-disease naïve-derived DN2: Naïve-derived DN2 cells prominently contribute to the early response to primary SARS-CoV-2 infection, with significant participation in generating neutralizing antibodies but also substantial autoreactivity through dual-reactive ASC with low or no SHM. In healthy subjects, these autoreactive responses subside within months — self-limited EF autoreactivity (see Sanz2025 - Human Atypical B Cells Overview, review citing Woodruff et al. 2020, 2022).

  • ABC as antigen-presenting cells: Across mouse and human studies, ABC/DN2 cells function as powerful APCs. This APC function may be important for TFH induction and sustainment of secondary GC responses. Excessive ABC APC activity has been proposed to cause abnormal TFH regulation, defective antigen-specific GC responses, and induction of autoreactivity (see Sanz2025 - Human Atypical B Cells Overview, review).

  • Distinction from HIV exhausted memory cells: SLE DN2 cells lack FCRL4 (which defines exhausted memory cells in HIV and tissue-resident memory in tonsil). DN2 cells express FCRL5 but retain intact proximal BCR signalling (BLNK phosphorylation after anti-IgG stimulation), unlike the functionally exhausted FCRL4⁺ cells in HIV (see Jenks2018 - DN2 B Cells and EF Pathway in SLE).

  • First infection context: DN2 expansion in severe COVID-19 mirrors active SLE: Critically ill COVID-19 patients (CoV-A cluster) showed DN2 expansion to ~80% of the DN compartment — matching active SLE. DN2 frequency of total CD19⁺ B cells was significantly higher in ICU-C than in OUT-C or HD (P ≤ 0.001). T-bet and CD11c expression (by intracellular staining) were highest in aN and DN2 populations. The EF cluster (aN + DN2 + DN3 + ASC expansion) defined the critically ill patient profile by hierarchical clustering (see Woodruff2020 - EF B Cell Responses in COVID-19, 24-marker spectral FCM, n=10 ICU-C, n=7 OUT-C, n=17 HD).

  • DN2:DN1 ratio in COVID-19 indistinguishable from SLE: log₂(DN2:DN1) in CoV-A was not significantly different from active SLE (both P ≤ 0.0001 vs. HD and CoV-B). This ratio is the most robust single metric of EF pathway activation across disease contexts (see Woodruff2020 - EF B Cell Responses in COVID-19).

  • DN2 frequency correlates with disease severity biomarkers: DN2 frequency within the DN compartment correlated with log(CRP) (r² = 0.39, P = 0.022). CRP in turn correlated with IL-6 (r² = 0.84) and IP-10/CXCL10 (r² = 0.58). This positions DN2 expansion as a direct cellular correlate of the inflammatory cascade associated with COVID-19 morbidity and mortality (see Woodruff2020 - EF B Cell Responses in COVID-19).

  • Chemokine receptor switch on DN2 cells: EF populations (aN, DN2) in CoV-A patients showed decreased CXCR5 and increased CXCR3 relative to follicular populations (rN, DN1) — consistent with homing to IFN-γ-inflamed tissue rather than B cell follicles (see Woodruff2020 - EF B Cell Responses in COVID-19).

  • EF activation not attributable to demographic baseline: African-American HD (n=24) showed slightly higher baseline DN2:DN1 ratios than the primary HD cohort, but remained significantly different from ICU-C — confirming that the DN2 expansion in severe COVID-19 is disease-driven (see Woodruff2020 - EF B Cell Responses in COVID-19).

  • EPIGENETIC CHARACTERISATION — DN2 closest to ASC by DNA methylation: Phylogenetic analysis of differentially methylated loci (DMLs) placed DN2 cells closest to ASCs in both SLE and HC, confirming their position as the most terminally differentiated non-ASC B cell subset. Progressive global hypomethylation from rN → T3 → aN → SM → DN2 → ASC establishes a linear epigenetic differentiation trajectory (see Scharer2019 - Epigenetic Programming in SLE B Cells, RRBS of 5 sorted subsets, n=9 SLE + n=12 HC).

  • DN2 chromatin driven by T-BET + AP-1 + EGR motifs: Motif enrichment of ATAC-seq DARs between DN2 and switched memory identified T-BET, ISGF3, AP-1 (JUN/FOSB/FOSL1/FOSL2), and EGR as the top DN2-enriched motifs. Switched memory was enriched for EBF, NF-κB, and OCT2 — confirming epigenetically distinct differentiation endpoints (see Scharer2019 - Epigenetic Programming in SLE B Cells).

  • T-BET chromatin programme shared by HC and SLE DN2 cells: The T-BET motif enrichment in DN2 accessible chromatin was present regardless of disease status, confirming that T-BET-driven epigenetic programming is a normal feature of DN2 differentiation. T-BET bound to its own TBX21 locus (autoregulatory loop) in both conditions (see Scharer2019 - Epigenetic Programming in SLE B Cells, ATAC-seq + ENCODE ChIP-seq).

  • AP-1/EGR amplification is SLE-specific: While T-BET motifs were shared, AP-1 and EGR accessibility was enhanced in SLE DN2 and aN cells relative to healthy counterparts. This identifies AP-1/EGR as the disease-specific epigenetic layer superimposed on the normal T-BET DN2 programme (see Scharer2019 - Epigenetic Programming in SLE B Cells).

  • ATF3 is a key SLE DN2-specific regulator: ATF3 was maximally expressed in SLE DN2 cells, validated at mRNA and protein levels. 98 ATF3 target genes were disease DEGs (87% upregulated). ATF3 motif accessibility was highest in SLE DN2 cells. ATF3 heterodimerises with Jun family members (JUN, JUNB, JUND — all upregulated in SLE DN2), shifting the equilibrium from repression to activation (see Scharer2019 - Epigenetic Programming in SLE B Cells).

  • DN2 cells lack G2/M checkpoint and apoptosis enrichment: While all other SLE B cell subsets showed enrichment for G2/M checkpoint and apoptosis pathways (GSEA), DN2 cells uniquely showed negative enrichment — potentially explaining their expansion in SLE by resistance to cell cycle arrest and apoptosis (see Scharer2019 - Epigenetic Programming in SLE B Cells).

  • PD-1 highest on DN2 cells: PDCD1 promoter and cis-regulatory elements were highly accessible in DN2 vs. switched memory. PD-1 protein was ~60% positive on DN2 cells vs. ~10–20% on other subsets (flow cytometry, n=4 SLE) (see Scharer2019 - Epigenetic Programming in SLE B Cells).

  • FIRST DENGUE EVIDENCE — CD21⁻CD11c⁺ B cells in acute dengue: Within the IgD⁻CD27⁻ (DN) gate, CD21⁻CD11c⁺ B cells — phenotypically consistent with DN2 — are significantly expanded in acute dengue vs. HD and convalescence. These cells emerge in the context of massive Peripheral Helper T Cell (CXCR5⁻PD-1⁺) activation providing IL-21, the same cytokine required for the aNAV→DN2→plasmablast pathway in SLE. Formal confirmation requires T-bet and CXCR5 staining within the DN gate, but the CD21/CD11c phenotype and cytokine milieu are consistent with DN2 identity (see Ansari2025 - Peripheral T Helper Subset Drives B Cell Response in Dengue, multi-color FCM, n=170 acute dengue adults).

Contradictions & Debates

  • DN2 cells were defined in SLE, where dysregulated TLR7 signalling is a disease-intrinsic feature. Whether the same DN2 phenotype and TLR7 hyper-responsiveness characterise EF B cells in acute viral infections (dengue, SARS-CoV-2, malaria) is not yet established. In infections, the TLR7 ligand is exogenous viral ssRNA rather than endogenous self-RNA; the signalling outcome may differ.
  • The relationship between DN2 cells and the “atypical memory B cells” described in malaria and HIV is phenotypically overlapping (both CD21⁻, CD27⁻, T-bet⁺) but functionally distinct: DN2 cells have intact BCR signalling and robust PC differentiation capacity, whereas malaria atypical memory cells show impaired BCR signalling and poor effector function. However, the exhaustion phenotype in malaria has been challenged — AtB cells may respond strongly to membrane-associated antigens and immune complexes even when hyporesponsive to soluble antigens (see Sanz2025 - Human Atypical B Cells Overview, review citing Holla et al. 2019).
  • Memory vs. effector DN2 cells: Post-SARS-CoV-2 vaccination, antigen-specific DN2 cells persist >1 year, accounting for >50% of all spike/RBD⁺ cells. This establishes the existence of durable CD27⁻ memory with DN2 phenotype. The full properties of memory DN2 (including their extended phenotype, T-bet expression, separation from effector DN2, and derivation from EF vs. GC pathways) remain to be elucidated (see Sanz2025 - Human Atypical B Cells Overview, review citing Faliti et al. 2024).
  • Whether the autoreactivity attributed to DN2 cells in SLE is a general property of the phenotype or specific to the autoimmune context is unresolved. Sanz (2025) argues that autoreactivity is context-dependent and should not be assumed from phenotype alone (see Sanz2025 - Human Atypical B Cells Overview).

Double-Negative B Cell, Activated Naive B Cell, Plasmablast, T-bet, CD11c, CXCR5, FCRL5, IRF4, BLIMP-1, BACH2, TRAF5, TLR7, ZEB2, ATF3, EGR, PD-1, Extrafollicular Response, Germinal Center

Sources

Graph View

Backlinks